Core Viewpoint - Alps Group Inc successfully completed its business combination with Globalink Investment Inc, marking a significant milestone as it prepares to list on the Nasdaq under the symbol "ALPS" on October 31, 2025 [1][4]. Business Combination Details - The business combination was executed under an Amended and Restated Merger Agreement, with multiple amendments leading up to the final agreement [2]. - The transaction involved a two-step merger process: a Redomestication Merger and an Acquisition Merger, resulting in Alps Group as the surviving publicly traded entity [3]. Trading and Valuation - Following the closing, Alps Group's ordinary shares will begin trading on Nasdaq, with an estimated enterprise value of approximately US$1.6 billion for the combined company [4]. Leadership and Governance - Post-closing, the headquarters of Alps Group will be in Kuala Lumpur, Malaysia, with Dr. Tham Seng Kong serving as the Chief Executive Officer and Chairman of the Board [5]. Strategic Vision - The CEO emphasized the mission to redefine healthcare through predictive, preventive, and precision medicine, aiming to make advanced healthcare accessible globally [6]. - The company plans to develop its BioValley initiative, a biotechnology hub to foster collaboration in the biotech ecosystem [8]. Financial Support - In connection with the business combination, Alps Group secured approximately US$3.1 million from PIPE Investors to support its growth strategy and working capital needs [6].

Group 1: Stock Price Movements - Globalink Investment Inc. experienced a significant surge, with its stock price jumping to $0.09, marking a 581.82% increase, driven by heightened investor interest possibly due to speculative activities or potential business combination news [1][6] - Cambium Networks Corporation saw its stock price rise to $2.66, a 331.65% increase, attributed to the integration of its Cambium ONE Network solution with Starlink satellite Internet services, enhancing its growth prospects [2][6] - Purple Biotech Ltd. witnessed its stock price increase to $0.93, up by 59.74%, driven by promising updates on its clinical trials and strategic partnerships, particularly regarding its tri-specific antibody IM1240 [3][6] - Ernexa Therapeutics Inc. saw its price increase to $1.97, a 57.85% rise, influenced by investor optimism towards its innovative therapies and a partnership with Cellipont Bioservices for clinical trials [4][6] - VSee Health, Inc. experienced a 49.52% increase in its stock price to $0.17, reflecting growing investor interest in the telehealth sector amid ongoing healthcare trends [5] Group 2: Market Trends and Investor Sentiment - The stock movements underscore the dynamic nature of the market, where company-specific developments, sector trends, and broader economic factors significantly impact stock prices [5] - Investors and analysts closely monitor such changes to gauge market sentiment and identify potential investment opportunities [5]

Business Combination and Mergers - The Company approved an amendment allowing an extension of the Termination Date to June 9, 2025, with a deposit of $60,000 for each monthly extension [178]. - The Company has extended the deadline for completing its initial business combination to September 9, 2025, having done so twenty-six times since the IPO [183]. - A Merger Agreement was entered into on January 30, 2024, with Alps Global Holding Pubco, involving a two-step merger process [184]. - The Company intends to use substantially all funds in the Trust Account to complete its business combination [207]. - The Company has a mandatory liquidation date of September 9, 2025, if a business combination is not consummated, raising substantial doubt about its ability to continue as a going concern [231]. Financial Performance - As of June 30, 2025, the Company reported a net loss of $1,632,451, which included interest expense of $736,826 and operating expenses of $604,083 [196]. - For the three months ended June 30, 2025, the Company had a net loss of $893,896, primarily due to interest expense of $451,629 and general administrative expenses of $333,827 [195]. - The Company reported cash used in operating activities of $430,447 for the six months ended June 30, 2025 [204]. - The Company generated non-operating income of $66,336 from interest on cash held in the Trust Account for the six months ended June 30, 2025 [206]. Shareholder Transactions - Holders of 2,285,056 shares redeemed their shares for cash at approximately $11.77 per share, totaling about $26.89 million, but were overpaid by $563,108 [179]. - The Company has recovered $397,214 of the overpayment made to redeeming shareholders as of the filing date [180]. - As of June 30, 2025, the PIPE Investors have subscribed for an aggregate of $3,479,911, excluding a terminated $40 million subscription [187]. - The Company is obligated to file a registration statement for the resale of all PIPE Shares within 60 days of the Closing [189]. Capital Structure and Debt - The Company has incurred significant costs in pursuing its acquisition plans, with no assurance of successful completion [176]. - The Company has entered into multiple promissory notes with Public Gold Marketing Sdn Bhd, totaling $2,000,000, all of which had been fully borrowed as of June 30, 2025 [210][211][212][213][214][216][218][219]. - The Company entered into multiple promissory notes with Public Gold Marketing Sdn. Bhd., totaling $1,650,000 for working capital, all bearing an interest of 6% per annum and fully borrowed by June 30, 2025 [220][222][223][224]. - As of June 30, 2025, the aggregate principal amount owed to related parties in connection with the promissory notes was $4,570,422, reflecting an increase from $4,445,458 as of December 31, 2024 [238]. - The total outstanding balance of promissory notes with Dr. Tham Seng Kong reached $650,000 as of June 30, 2025, following an additional withdrawal of $200,000 [226]. - The Company has no long-term debt, capital lease obligations, or off-balance sheet arrangements as of June 30, 2025 [232][233]. Regulatory and Compliance - The Company received Nasdaq's approval for the transfer of its securities from the Nasdaq Global Market to the Nasdaq Capital Market on March 6, 2024 [190]. - The Company’s securities were suspended from trading on Nasdaq on December 17, 2024, and subsequently delisted effective May 19, 2025 [192]. - The Company is evaluating the benefits of relying on reduced reporting requirements under the JOBS Act, which may affect its compliance with new accounting standards [241]. - The Company is classified as a smaller reporting company and is not required to provide certain market risk disclosures [247]. Accounting and Financial Reporting - The Company accounts for warrants as either equity-classified or liability-classified instruments based on specific terms and applicable guidance [245]. - Public warrants meet the criteria for equity treatment, while private warrants are classified as liabilities and recorded at fair value [245]. - As of June 30, 2025, the Private Placement Warrants were valued using the observable price for the public warrant as a benchmark [245]. - In December 2023, the FASB issued ASU 2023-09, which requires expanded disclosures of income taxes paid effective for fiscal years beginning after December 15, 2024 [246]. - The Company's management is evaluating the impact of ASU 2023-09 on its consolidated financial statements [246]. IPO and Capital Raising - The Company completed its IPO on December 9, 2021, raising gross proceeds of $100,000,000 from the sale of 10,000,000 units at $10.00 per unit [199]. - The PIPE Investment aims to raise additional capital for PubCo, with agreements totaling $3,279,911 at a purchase price of $10.00 per share [187]. - The underwriters are entitled to a deferred underwriting discount of $4,025,000, which will be payable only if the Company completes an initial business combination [235].

Company Overview - Globalink Investment Inc. is a special purpose acquisition company (SPAC) formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more businesses [2] - The company has no restrictions on the industry or geographic region for its targets, but it intends to focus on the medical technology and green energy sectors in North America, Europe, Southeast Asia, and Asia (excluding China, Hong Kong, and Macau) [2] Recent Developments - On April 8, 2025, Globalink deposited $60,000 into its trust account to extend the deadline for completing its initial business combination from April 9, 2025, to May 9, 2025 [1] - This extension marks the twenty-second extension since the company's initial public offering on December 9, 2021, and is the fifth of up to six extensions allowed under its governing documents [1]